🇺🇸 FDA
Patent

US 8685404

Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction

granted A61KA61K2039/605A61K39/0007

Quick answer

US patent 8685404 (Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction) held by United States Government as represented by the Department of Veterans Affairs expires Mon Mar 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
United States Government as represented by the Department of Veterans Affairs
Grant date
Tue Apr 01 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
28
CPC classes
A61K, A61K2039/605, A61K39/0007, A61K39/0013, A61K45/06